THE MICHIGAN DEPARTMENT OF COMMUNITY HEALTH
BUREAU OF LABORATORIES

MATERIAL TRANSFER AGREEMENT¹

I. DEFINITIONS:

A. PROVIDER: MICHIGAN DEPARTMENT OF COMMUNITY HEALTH

B. PROVIDER SCIENTIST:

C. RECIPIENT:

D. RECIPIENT SCIENTIST

E. ORIGINAL MATERIAL:

EE. RESEARCH PURPOSE:

F. MATERIAL: ORIGINAL MATERIAL, PROGENY, and UNMODIFIED DERIVATIVES. The MATERIAL shall not include: (a) MODIFICATIONS, or (b) other substances created by the RECIPIENT through the use of the MATERIAL which are not MODIFICATIONS, PROGENY, or UNMODIFIED DERIVATIVES.

G. PROGENY: Unmodified descendant from the MATERIAL, such as virus from virus, cell from cell, or organism from organism.

H. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT which constitute an unmodified functional sub-unit or product expressed by the ORIGINAL MATERIAL. Some examples include: subclones of unmodified cell lines, purified or fractionated subsets of the ORIGINAL MATERIAL, proteins expressed by DNA/RNA supplied by the PROVIDER, or monoclonal antibodies secreted by a hybridoma cell line.

I. MODIFICATIONS: Substances created by the RECIPIENT which contain/incorporate the MATERIAL.

¹ Although not a signatory to the Association of University Technology Managers (“AUTM”), the MDCH has adopted the definitions, terms, and conditions of the Uniform Biological Material Transfer Agreement (“UBMTA”) published in the Federal Register, vol. 60, March 8, 1995, page 12771 et seq., with the following exception. MDCH has added additional terms and conditions, as set out in Part B below, that applies only to the transfer of newborn screening specimens for research.
J. COMMERCIAL PURPOSES: The sale, lease, license, or other transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. COMMERCIAL PURPOSES shall also include uses of the MATERIAL or MODIFICATIONS by any organization, including RECIPIENT, to perform contract research, to screen compound libraries, to produce or manufacture products for general sale, or to conduct research activities that result in any sale, lease, license, or transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. However, industrially sponsored academic research shall not be considered a use of the MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES per se, unless any of the above conditions of this definition are met.

K. NONPROFIT ORGANIZATION(S): A university or other institution of higher education or an organization of the type described in section 501(c)(3) of the Internal Revenue Code of 1954 (26 U.S.C. 501(c)) and exempt from taxation under section 501(a) of the Internal Revenue Code (26 U.S.C. 501(a)) or any nonprofit scientific or educational organization qualified under a state nonprofit organization statute. As used herein, the term also includes government agencies.

PART A

II. TERMS AND CONDITIONS OF THIS AGREEMENT THAT APPLY TO ALL TRANSFERS OF MATERIAL

A. The PROVIDER retains ownership of the MATERIAL, including any MATERIAL contained or incorporated in MODIFICATIONS.

B. The RECIPIENT retains ownership of:

1. MODIFICATIONS (except that, the PROVIDER retains ownership rights to the MATERIAL included therein), and

2. those substances created through the use of the MATERIAL or MODIFICATIONS, but which are not PROGENY, UNMODIFIED DERIVATIVES or MODIFICATIONS (i.e., do not contain the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES).

If either B.1 or 2 above results from the collaborative efforts of the PROVIDER and the RECIPIENT, joint ownership may be negotiated.

C. The RECIPIENT and the RECIPIENT SCIENTIST agree that the MATERIAL:

1. is to be used solely for teaching and academic research purposes;
2. will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects without the written consent of the PROVIDER;

3. is to be used only at the RECIPIENT organization and only in the RECIPIENT SCIENTIST's laboratory under the direction of the RECIPIENT SCIENTIST or others working under his/her direct supervision; and

4. will not be transferred to anyone else within the RECIPIENT organization without the prior written consent of the PROVIDER.

D. The RECIPIENT and the RECIPIENT SCIENTIST agree to refer to the PROVIDER any request for the MATERIAL from anyone other than those persons working under the RECIPIENT SCIENTIST's direct supervision. To the extent supplies are available, the PROVIDER or the PROVIDER SCIENTIST agrees to make the MATERIAL available, under a separate agreement having terms consistent with the terms of this Agreement, to other scientists (at least those at NONPROFIT ORGANIZATION(S)) who wish to replicate the RECIPIENT SCIENTIST's research; provided that such other scientists reimburse the PROVIDER for any costs relating to the preparation and distribution of the MATERIAL.

1. The RECIPIENT and/or the RECIPIENT SCIENTIST shall have the right, without restriction, to distribute substances created by the RECIPIENT through the use of the ORIGINAL MATERIAL only if those substances are not PROGENY, UNMODIFIED DERIVATIVES, or MODIFICATIONS.

2. Under a separate agreement at least as protective of the PROVIDER's rights, the RECIPIENT may distribute MODIFICATIONS to NONPROFIT ORGANIZATION(S) for research and teaching purposes only.

3. Without written consent from the PROVIDER, the RECIPIENT and/or the RECIPIENT SCIENTIST may NOT provide MODIFICATIONS for COMMERCIAL PURPOSES. It is recognized by the RECIPIENT that such COMMERCIAL PURPOSES may require a commercial license from the PROVIDER and the PROVIDER has no obligation to grant a commercial license to its ownership interest in the MATERIAL incorporated in the MODIFICATIONS. Nothing in this paragraph, however, shall prevent the RECIPIENT from granting commercial licenses under the RECIPIENT's intellectual property rights claiming such MODIFICATIONS, or methods of their manufacture or their use.

E. The RECIPIENT acknowledges that the MATERIAL is or may be the subject of a patent application. Except as provided in this Agreement, no express or implied licenses or other rights are provided to the RECIPIENT under any patents, patent applications, trade secrets or other proprietary rights of the
provided to use the MATERIAL, MODIFICATIONS, or any related patents of the PROVIDER for COMMERCIAL PURPOSES.

F. If the RECIPIENT desires to use or license the MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES, the RECIPIENT agrees, in advance of such use, to negotiate in good faith with the PROVIDER to establish the terms of a commercial license. It is understood by the RECIPIENT that the PROVIDER shall have no obligation to grant such a license to the RECIPIENT, and may grant exclusive or non-exclusive commercial licenses to others, or sell or assign all or part of the rights in the MATERIAL to any third party(ies), subject to any pre-existing rights held by others and obligations to the Federal Government.

G. The RECIPIENT is free to file patent application(s) claiming inventions made by the RECIPIENT through the use of the MATERIAL but agrees to notify the PROVIDER upon filing a patent application claiming MODIFICATIONS or method(s) of manufacture or use(s) of the MATERIAL.

H. Any MATERIAL delivered pursuant to the Agreement is understood to be experimental in nature and may have hazardous properties. The PROVIDER MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. The Recipient is responsible for maintaining a safe working environment in Recipient’s laboratory through adequate training of personnel (including students), facility design, personal protective equipment availability and proper disposal of waste.

I. Except to the extent prohibited by law, the RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of the MATERIAL. The PROVIDER will not be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against the RECIPIENT by any other party, due to or arising from the use of the MATERIAL by the RECIPIENT, except to the extent permitted by law when caused by the gross negligence or willful misconduct of the PROVIDER.

II. MDCH represents and warrants that it has obtained review and approval from the MDCH Institutional Review Board for transfer of MATERIAL to __________________________________________including but not limited to
review of the specific material, the proposed use, and the patient consents under which the materials were obtained.”

J. This agreement shall not be interpreted to prevent or delay publication of research findings resulting from the use of the MATERIAL or the MODIFICATIONS. The RECIPIENT SCIENTIST agrees to provide appropriate acknowledgement of the source of the MATERIAL in all publication.

K. The RECIPIENT agrees to use the MATERIAL in compliance with all applicable statutes and regulations, including Public Health Service and National Institutes of Health regulations and guidelines such as, for example, those relating to research involving the use of animals or recombinant DNA.

L. This Agreement will terminate on the earliest of the following dates:

1. when the MATERIAL becomes generally available from third parties, for example, through reagent catalogs or public depositories, or

2. on completion of the RECIPIENT’s current research with the MATERIAL, or

3. on thirty (30) days written notice by either party to the other,

provided that:

a. if termination should occur under L.1 the RECIPIENT shall be bound to the PROVIDER by the least restrictive terms applicable to the MATERIAL obtained from the then-available sources; and

b. if termination should occur under L.2., the RECIPIENT will discontinue its use of the MATERIAL and will, upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either destroy the MODIFICATIONS or remain bound by the terms of this agreement as they apply to MODIFICATIONS; and

C. in the event the PROVIDER terminates this Agreement under L.3. other than for breach of this Agreement or for cause such as an imminent health risk or patent infringement, the PROVIDER will defer the effective date of termination for a period of up to one year, upon request from the RECIPIENT, to permit completion of research in progress. Upon the effective date of termination, or if requested, the deferred effective date of termination, RECIPIENT will discontinue its use of the MATERIAL and will, upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either destroy the MODIFICATIONS or remain bound by the terms of this agreement as they apply to MODIFICATIONS.
M. Paragraphs F, I and J shall survive termination.

N. The **MATERIAL** is provided at no cost, or with an optional transmittal fee determined by the Michigan Neonatal Biobank solely to reimburse the **PROVIDER** for its preparation and distribution costs.

NN. Neither party shall use the name of the other or any contraction or derivative thereof or the name(s) of the other party's faculty members, employees, or students, as applicable, in any advertising, promotional, sales literature, or fundraising documents without prior written consent from the other party.

O. This Agreement may not be amended without the prior written consent of both parties.

P. This Agreement constitutes the entire agreement between the parties relating to the subject matter and supersedes any prior agreements, written or oral, regarding the subject matter hereof.

**PART B**

**III. ADDITIONAL TERMS AND CONDITIONS OF THIS AGREEMENT THAT APPLY TO TRANSFER OF NEWBORN SCREENING SPECIMENS FOR RESEARCH**

A. **RECIPIENT** agrees to provide the following information to **PROVIDER**, which will be publicly posted and made available by **PROVIDER** to engage and inform the public about research that uses newborn screening specimens:

1. Summary or abstract describing the research project to be provided before newborn screening specimens are transferred to **RECIPIENT**.

2. Summary of the research project results to be provided within 1 year of research completion or no later than the acceptance for publication, whichever comes first. Upon request from **RECIPIENT**, 1-year deadline may be extended by **PROVIDER** for good cause. The **PROVIDER** will be given citation(s) for all published work utilizing the newborn screening specimens.

3. Within 6 months of research completion, **RECIPIENT** will complete and return Appendix A: Dried Blood Spot Final Inventory Log.
IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives effective as of the date last written below.

______________________________________________
University/Agency/Institution

______________________________________________
Street

City, State ZIP

Name:__________________________________________ Title:

Signature:__________________________ Date:________

MICHIGAN DEPARTMENT OF COMMUNITY HEALTH
BUREAU OF LABORATORIES
3350 N Martin Luther King, Jr. Blvd.
Lansing, Michigan 48909

Name:
Title: Laboratory Director
Signature: Date:
THE MICHIGAN DEPARTMENT OF COMMUNITY HEALTH BUREAU OF LABORATORIES

MATERIAL TRANSFER AGREEMENT

Appendix A: DRIED BLOOD SPOT (DBS) FINAL INVENTORY LOG

(To be returned to MICHIGAN DEPARTMENT OF COMMUNITY HEALTH/BUREAU OF LABORATORIES when study is completed)

PRINCIPAL INVESTIGATOR: 

COLLABORATOR (IF INDICATED): 

STUDY TITLE: 

DBS RECIPIENT ADDRESS: 

QUANTITY ACQUIRED: Please indicate the number of samples received as well as the number and size of punches or number of spots per sample.

   Number of DBS Samples: 
   Size of DBS Samples:
      Number and Size of Punches: 
      Number of Whole Dried Blood Spots: 

DATE OF ACQUISITION: 

FINAL INVENTORY OF USAGE: Please confirm that all dried blood spots and related materials were used in their entirety or destroyed at the completion of the study.

☐ DBS and Related Material Used in Entirety      ☐ DBS and Related Material Destroyed

PRINCIPAL INVESTIGATOR: 
DATE: 

COLLABORATOR (IF INDICATED): 
DATE: 

COMMENTS: 

Rev. 06/2013